ArticleMedicine2025
CD5 mediates the link between CD4+ CD39+ activated Treg cells and gastric cancer: A Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gastric cancer (GC) remains one of the leading causes of cancer mortality worldwide. The tumor immune microenvironment plays a pivotal role in GC progression, with regulatory T cells (Tregs), particularly the CD4+ CD39+ subset, implicated in immune suppression. However, the causal role of CD4+ CD39+ Treg cells in GC remains unclear. Additionally, CD5, a T cell surface glycoprotein, may influence immune responses in cancer. This study aims to clarify the relationship between CD4+ CD39+ Treg cells and GC risk and explore the potential mediating role of CD5 using a Mendelian randomization (MR) approach. A bidirectional 2-sample MR analysis was conducted using genome-wide association study data. CD4+ CD39+ Treg cell data were sourced from the IEU genome-wide association study database (N = 2920), and GC data were retrieved from the FennGenn consortium (N = 2,88,444; 1307 cases, 2,87,137 controls). Analyses included inverse variance weighted, MR-Egger regression, weighted median, and Mendelian randomization-Pleiotropy RESidual Sum and Outlier to test robustness and pleiotropy. A 2-step MR was performed to evaluate the mediating role of CD5. Results indicated that increased CD4+ CD39+ Treg cell levels were associated with a reduced risk of GC (odds ratio [OR] = 0.907, 95% confidence interval [CI] = 0.829-0.993, P = .035). No heterogeneity or pleiotropy was observed, and reverse causality was excluded (OR = 0.983, 95% CI = 0.931-1.038, P = .530). Additionally, CD4+ CD39+ Treg cells influenced CD5 expression (OR = 0.970, 95% CI = 0.943-0.998, P = .035), and elevated CD5 levels were linked to increased GC risk (OR = 1.285, 95% CI = 1.030-1.603, P = .026). Mediation analysis revealed that CD5 accounted for 7.74% of the protective effect of CD4+ CD39+ Treg cells on GC. CD4+ CD39+ Treg cells are causally linked to a reduced risk of GC, with CD5 mediating a small but significant portion of this protective effect. These findings highlight the importance of immune regulation in GC and suggest that targeting CD5 could be a therapeutic strategy. Further research is needed to investigate additional mediators contributing to GC development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.